Inflammatory responses in the atria: should they stay or should they go?

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Heart Rhythm

• Publication date

  2011-02-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1016/j.hrthm.2010.11.006PMID 21056699PMCID PMC3058228
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pioglitazone

  2012cited by this paper
• The resolution of inflammation: anti-inflammatory roles for NF-kappaB.

  2010cited by this paper
• Recruitment of immune cells across atrial endocardium in human atrial fibrillation.

  2010cited by this paper
• Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats.

  2010cited by this paper
• Brown vs white adipocytes: The PPARγ coregulator story

  2010cited by this paper
• Cardiac Disorders as Risk Factors for Alzheimer's Disease

  2010cited by this paper
• Current perceptions of the epidemiology of atrial fibrillation.

  2009cited by this paper
• Integrins and proximal signaling mechanisms in cardiovascular disease.

  2009cited by this paper
• Clinical, Economic, and Quality of Life Impact of Atrial Fibrillation

  2009cited by this paper
• Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure.

  2008cited by this paper
• Peroxisome Proliferator-Activated Receptors (PPARs) and the Human Skin

  2008cited by this paper
• Is there a role for remodeled connexins in AF? No simple answers.

  2008cited by this paper
• Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation

  2008cited by this paper
• Abstract 1343: Atrial Cardiomyocyte Tachycardia Alters Cardiac Fibroblast Function: A Novel Consideration in Atrial Remodeling

  2007cited by this paper
• Atrial Fibrillation and Stroke in the General Medicare Population: A 10-Year Perspective (1992 to 2002)

  2006cited by this paper
• Peroxisome proliferator-activated receptor-γ: therapeutic target for diseases beyond diabetes: quo vadis?

  2004cited by this paper
• The Role of Glial Reaction and Inflammation in Parkinson's Disease

  2003cited by this paper
• PPARgamma and atherosclerosis: effects on cell growth and movement.

  2001cited by this paper
• PPARγ and Atherosclerosis

  2001cited by this paper
• The glitazones: proceed with caution.

  2000cited by this paper
• Thiazolidinediones--the new insulin enhancers.

  1999cited by this paper
• PPAR-γ agonists inhibit production of monocyte inflammatory cytokines

  1998cited by this paper
• The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

  1998cited by this paper
• PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

  1998cited by this paper
• The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

  1998cited by this paper

• Role of connexins and pannexins in cardiovascular physiology

  2015cites this paper